Skip to content

Molecular and cellular neurosciences

ISSN 1095-9327

2 papers in the library · 3 citations · publishing 2025-2026

Papers

Single subanesthetic dose of ketamine exerts antioxidant and antidepressive-like effect in ACTH-induced preclinical model of depression.

Molecular and cellular neurosciences June 1, 2025 Ana Ivanović, Jelena Petrović, Dušanka Stanić et al. 3 citations

A single subanesthetic dose of ketamine (10 mg/kg) reduced depressive-like behavior and oxidative stress in a rodent model of treatment-resistant depression induced by adrenocorticotropic hormone (ACTH). ACTH increased superoxide anion, advanced oxidation protein products, malondialdehyde, and total oxidant status, while decreasing superoxide dismutase and paraoxonase1 activity and increasing DNA damage in peripheral blood lymphocytes. Ketamine reversed these effects, lowering oxidative markers and enhancing antioxidant enzyme activity. The findings suggest ketamine's antidepressant action may involve antioxidant mechanisms, supporting further clinical research on its effects on reactive oxygen species metabolism and antioxidant defenses in depression.

Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.

Molecular and cellular neurosciences March 1, 2026 Mustafa M Shokr, Mohamed N Fawzy, Ahmed M Abdelaziz

The brain's ability to reorganize itself, known as neuroplasticity, is now understood to be more flexible and treatable in adults than previously believed. This review examines drugs that target key synaptic receptors (NMDA, AMPA, GABA), neuropeptide systems (BDNF, oxytocin, vasopressin), and psychedelic compounds (psilocybin, LSD, ketamine). Evidence shows that NMDA antagonists produce rapid antidepressant effects, classic psychedelics reorganize brain structure and function through 5-HT2A receptor activation, and neuropeptides support synaptic repair. The authors emphasize safety concerns, risks of harmful plasticity, and the need for controlled dosing and patient selection. Emerging non-hallucinogenic neuroplastogens and combination therapies may offer safer ways to enhance plasticity for treating neuropsychiatric and neurodegenerative disorders.